Increasing the detection sensitivity while extending simultaneously the analysis to numerous biomarkers simultaneously (multiplexing) are essential breakthroughs to be addressed for improving significantly the field of biomedical analysis. Such progresses would allow earlier diagnostics and a better differentiation in pathologies as is currently required for numerous diseases and in particular for septic shocks and severe sepsis, opening the way to personalized treatments to the concomitant benefits of the patients and of the social care administrations. Advances in multiplexed analysis are also a crucial ask from pharmaceutical industries within the frame of their research programs on high throughput screenings. Fluoro-immunnoassays are based on the biomolecular recognition events that occur between biomarkers and specific antibodies labelled with fluorescent dyes. Upon the immune interaction, the spatial proximity can lead to resonant energy transfer processes (RET) that can be monitored to quantify the biomarkers concentrations. But if the development of monoclonal antibodies provides very specific interactions with the antigens, the current use of conventional fluorescent labels severely restricts the detection sensitivity and the possibility of multiplexed analysis on a single sample. The NanoFRET project aims at exploiting the exceptional spectroscopic properties of luminescent semiconducting nanocrystals (Quantum Dots, QDs) to provide ultrasensitive multiplexed fluoroimmunoassays. By combining CdSe based QDs with lanthanide complexes, we recently demonstrated that one can significantly increase the sensitivity of FRET associated signals, and that such analysis can be conducted on up to five different recognition events in a same sample (multiplexing). Within the NanoFRET project, we intend to enlarge the proof of concept obtained from the biotin-streptavidin interaction to immunocomplexes formed between antigens and antibodies, by addressing the nanocrystals with antibodies at their surface. In particular, we will focus our attention on the detection of procalcitonin (PCT) and proadrenomedulin (PAM), biological marker of systemic inflammatory reaction and of severe sepsis, the early detection of which would lead to the development of improved treatment and therapy. NanoFRET is based on the partnership of three public research teams, internationally recognized within the fields of luminescent semiconducting nanoparticles, lanthanide complexes for biolabelling and energy transfer phenomena, associated with a French industrial partner, specialized in clinical diagnostic and in the development of fluoroimmunoassays. It aims at bringing the exploratory results yet obtained (and protected by patents of the CNRS and the CEA) at and applied level targeted towards sepsis detection, while covering the aspects of a potential industrial development. This highly pluridisciplinary research program will allow the transfer of a fundamental technology to the industrial partner and aims at bringing significant breakthroughs within the fields of health nanotechnologies by addressing innovative nanosystems based on quantum dots.